Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib Plus Obinutuzumab in Previously Untreated Classical Hairy Cell Leukemia
NCT03410875Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2018
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of vemurafenib, obinutuzumab in hairy cell leukemia (HCL), sponsored by Memorial Sloan Kettering Cancer Center. Started Feb 2018; status: active, not recruiting.
02
Drugs
vemurafenibobinutuzumab
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on NCT03410875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03410875.